ReviewAdvances in experimental medicine and biology2025
Beyond Infections: Exploring Immune-Mediated Pathways Linking Cannabis and Emerging Environmental Contaminants to Neurodevelopmental Outcomes.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of olanzapine on changes in serum complement factors levels in patients with first-episode schizophrenia.BMC psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of the brain is a highly coordinated process that begins early in gestation and relies on intricate interactions between maternal and fetal immune systems. Disruptions to this delicate prenatal immune environment can significantly impact fetal brain development, increasing the risk of a spectrum of neurological and behavioral disorders, including autism spectrum disorder (ASD), schizophrenia, depression, and anxiety. While maternal exposure to viral and bacterial infections has been extensively studied as a driver of these disruptions, emerging research highlights the potential role of non-infectious exposures-such as drugs of abuse and environmental contaminants-in shaping neurodevelopmental outcomes. This issue has gained urgency with the rising prevalence of neurodevelopmental disorders; in the United States, for instance, ASD diagnoses have surged from 1 in 150 children in the early 2000s to 1 in 36 by 2020. Within this context, the increasing detection of cannabis, micro- and nanoplastics (MPs/NPs), and flame retardants in maternal and fetal tissues warrants close scrutiny. These substances, which are growing in prevalence due to changing societal norms, widespread environmental pollution, and industrial practices, may disrupt neurodevelopment through immune-mediated mechanisms. Cannabis use during pregnancy, for example, has increased significantly with legalization, while MPs/NPs and flame retardants are now frequently detected in maternal blood, placenta, and breast milk, raising concerns about their impacts on fetal health. In this chapter, we summarize human and preclinical evidence to explore how perinatal exposure to these substances may alter neurodevelopment by disrupting maternal and/or fetal immunity. We begin with an overview of central nervous system development and the critical role of immune interactions in ensuring a healthy pregnancy. We then review evidence linking perinatal exposure to cannabis, MPs/NPs, and flame retardants to neurodevelopmental outcomes, emphasizing immune-mediated pathways such as alterations in cytokine production, microglial activation, and adaptive immune cell function. Finally, we identify key gaps in the literature and propose future research directions to better understand the complex interplay between environmental exposures, immune dysregulation, and neurodevelopmental outcomes.
Indexed as
Identifiers
40442391What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.